IP Library › Granted Patent US 7,683,076

Granted Patent B2

US 7,683,076 · App. 10/578,413 · Granted Mar 23, 2010

Tetrahydro-quinolinylurea derivatives

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,683,076
App. No.: 10/578,413
Granted: Mar 23, 2010
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

Claims (128)

1. A urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

—X— represents a bond, —O— or —N(R 10 )— (wherein R 10 is hydrogen or C 1-6 alkyl);

with the proviso that when m is 0, —X— represents a bond,

R A and R B represent hydrogen, or

R A and R B together form a carbonyl-group with the carbon-atom to which they are connected,

R 1 represents aryl or heteroaryl

wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, C 1-6 alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl), sulfonamide, C 1-6 alkanoyl, C 1-6 alkanoylamino, carbamoyl, C 1-6 alkylcarbamoyl, cyano, C 1-6 alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C 1-6 alkoxycarbonyl or mono-, di-, or tri-halogen), C 1-6 alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl or C 1-6 alkyl), C 1-6 alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C 3-8 cycloalkyl, and heterocycle; and

R 2 represents C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, hydrogen, hydroxy,

aryl, heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, C 3-8 cycloalkyl, amino, N-(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C 1-6 alkyl)aminocarbonyl, or N,N,-di(C 1-6 alkyl)aminocarbonyl, and

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C 1-6 alkoxy)carbonyl, C 3-8 cycloalkyl, amino, N-(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C 1-6 alkyl)aminocarbonyl, N,N-di(C 1-6 alkyl)aminocarbonyl, C 1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C 1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.

2. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

—X— represents a bond, —O— or —N(R 10 )— (wherein R 10 is hydrogen or C 1-6 alkyl);

with the proviso that when m is 0, —X— represents a bond,

R A and R B represent hydrogen,

R 1 represents aryl or heteroaryl

R 2 represents C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, hydrogen, hydroxy,

aryl, heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,

wherein

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C 1-6 alkoxy)carbonyl, C 3-8 cycloalkyl, amino, N-(C 1-6 alkyl)amino, N,N-di(C 1-6 -alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C 1-6 -alkyl)aminocarbonyl, N,N-di-(C 1-6 -alkyl)aminocarbonyl, C 1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C 1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.

3. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

—X— represents a bond, —O— or —N(R 10 )— (wherein R 10 is hydrogen or C 1-6 alkyl);

with the proviso that when m is 0, —X— represents a bond,

R A and R B represent hydrogen,

R 1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, C 1-6 alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl), sulfonamide, C 1-6 alkanoyl, C 1-6 alkanoylamino, carbamoyl, C 1-6 alkylcarbamoyl, cyano, C 1-6 alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C 1-6 alkoxycarbonyl or mono-, di-, or tri-halogen), C 1-6 alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl or C 1-6 alkyl), C 1-6 alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C 3-8 cycloalkyl, and heterocycle; and

R 2 represents C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, hydrogen, hydroxy,

aryl, heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,

wherein

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

4. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

—X— represents a bond, —O— or —N(R 10 )— (wherein R 10 is hydrogen or C 1-6 alkyl);

with the proviso that when m is 0, —X— represents a bond,

R A and R B represent hydrogen,

R 1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

R 2 represents C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, hydrogen, hydroxy,

phenyl, naphthyl, pyridyl, of pyrimidyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, phenysulfonyl, pyrimidylsulfonyl, or pyridylsulfonyl,

wherein

said cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, phenyl moiety, pyridyl moiety or pyrimidyl moiety of said phenylsulfonyl, pyridylsulfonyl, pyrimidyl-sulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C 1 -alkoxy)carbonyl, C 3-8 cycloalkyl, amino, N-(C 1-6 -alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C 1-6 alkyl)aminocarbonyl, N,N-di (C 1-6 alkyl)-aminocarbonyl, C 1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C 1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.

5. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

m represents 0, 1, 2, or 3;

p represents 0;

—X— represents a bond;

R A and R B represent hydrogen,

R 1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

R 2 represents C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, hydrogen, hydroxy,

phenyl, naphthyl, pyridyl, of pyrimidyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, phenylsulfonyl, pyrimidylsulfonyl, or pyridylsulfonyl,

wherein

said cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, phenyl moiety, pyridyl moiety or pyrimidyl moiety of said phenylsulfonyl, pyridylsulfonyl, pyrimidylsulfonyl are optionally substituted by

6. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

m represents 1, 2, or 3;

p represents 0, 1, 2, or 3;

—X— represents a bond, —O— or —N(R 10 )— (wherein R 10 is hydrogen or C 1-6 alkyl);

R A and R B represent hydrogen,

R 1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

R 2 represents C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, hydrogen, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 3-8 cycloalkyl,

wherein

said alkyl, alkenyl, cycloalkyl, or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, C 3-8 cycloalkyl, amino, N-(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C 1-6 alkyl)aminocarbonyl, or N,N,-di(C 1-6 alkyl)aminocarbonyl.

7. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

m represents 0;

p represents 0;

—X— represents —O— or —N(R 10 )— (wherein R 10 is hydrogen or C 1-6 alkyl);

R A and R B represent hydrogen,

R 1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

R 2 represents C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, hydrogen, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 3-8 cycloalkyl,

wherein

8. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

m represents 1, 2, or 3;

p represents 0, 1, 2, or 3;

—X— represents a bond, —O— or —N(R 10 )— (wherein R 10 is hydrogen or C 1-6 alkyl);

R A and R B represent hydrogen,

R 1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, C 1-6 alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkyl-amino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl), sulfonamide, C 1-6 alkanoyl, C 1-6 alkanoylamino, carbamoyl, C 1-6 alkylcarbamoyl, cyano, C 1-6 alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C 1-6 alkoxycarbonyl or mono-, di-, or tri-halogen), C 1-6 alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 3-8 cycloalkylamino, or C 1-6 alkoxycarbonyl or C 1-6 alkyl), C 1-6 alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C 3-8 cycloalkyl, and heterocycle; and

R 2 represents hydrogen, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 3-8 cycloalkyl.

9. The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 ,

wherein

R 1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein said phenyl, naphthyl, pyridyl, or pyrimidyl is optionally substituted by one or more of substituents selected from the group consisting of chloro, bromo, fluoro, nitro, methoxy, trifluoromethyl, trifluoromethoxy and C 1-6 alkanoylamino.

10. The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1 , wherein said urea derivative of the formula (I) is selected from the group consisting of:

N-(4-chlorophenyl)-N-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-N-(3-hydroxy-1-methyl -1,2,3,4-tetrahydroquinolin-5-yl)urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-N-(3-hydroxy-1,2,3,4-tetrahydroquinolin-5-yl) urea;

ethyl 3-({[(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)amino]carbonyl} amino)- benzoate;

N-biphenyl-3-yl-N-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea, and

the salts thereof.

11. A pharmaceutical composition comprising a urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.

12. The pharmaceutical composition as claimed in claim 11 , further comprising one or more pharmaceutically acceptable excipients.

13. The pharmaceutical composition as claimed in claim 11 , wherein said urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.

14. The for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 .

15. The method as claimed in claim 14 , wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.

Assignments (1)

MERGER Recorded Jan 12, 2010

From: BAYER HEALTHCARE AG

To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Reel/Frame 023769/0122 →